for indoleamine 2,3-dioxygenase 1 (IDO1). CpG-ODN has been reported to induce unexpected IDO1 expression, which leads to poor clinical outcomes by suppressing immune surveillance in the tumor ...

In particular, higher levels of an enzyme called indoleamine-2,3,-dioxygenase 1 (IDO1) have been reported in the brains of ...

Selective inhibition of indoleamine and tryptophan 2,3-dioxygenases: Comparative study on kynurenine pathway in cell lines via LC-MS/MS-based targeted metabolomics.

The leading Melanoma Companies such as IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, BioNTech SE, TILT Biotherapeutics ...

Despite promising Phase II data, there was no difference in overall survival between the patients who received Canvaxin and the patients who received placebo in the randomized Phase III trial of ...